Queen's University of Belfast and AilseVax Limited KTP 23_24 R3
Lead Participant:
QUEEN'S UNIVERSITY BELFAST
Abstract
To develop and embed a new platform for the rapid identification and validation of cancer vaccine antigen candidates to generate next generation cancer vaccines with broader and enhanced efficacy.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| QUEEN'S UNIVERSITY BELFAST | £309,943 | £ 207,662 |
Participant |
||
| INNOVATE UK | ||
| AILSEVAX LIMITED | ||
| KTN LTD | ||
| Hartpury University |
People |
ORCID iD |